Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Low-titer group O whole blood (LTOWB) is a hemostatic resuscitation product used for the emergency management of hemorrhagic shock and massive blood loss. Unlike conventional component therapy, which involves the separate administration of packed red blood cells, plasma, and platelets, LTOWB provides these components in their natural physiological ratio within a single unit. It is collected from group O donors specifically screened for low titers of anti-A and anti-B antibodies (typically < 1:64 or < 1:256) to reduce the risk of acute hemolytic transfusion reactions in non-group O recipients. This product is particularly utilized in prehospital, military, and emergency department settings due to its logistical simplicity and its ability to rapidly restore oxygen-carrying capacity and hemostatic function while minimizing the dilutional effects of additives found in components.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on low-titer group O whole blood.